We feel now is a pretty good time to analyse Citius Oncology, Inc.'s (NASDAQ:CTOR) business as it appears the company may be on the cusp of a considerable accomplishment. Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. The US$77m market-cap company posted a loss in its most recent financial year of US$25m and a latest trailing-twelve-month loss of US$43m leading to an even wider gap between loss and breakeven. The most pressing concern for investors is Citius Oncology's path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Citius Oncology is bordering on breakeven, according to some American Biotechs analysts. They expect the company to post a final loss in 2026, before turning a profit of US$12m in 2027. So, the company is predicted to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 60%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of Citius Oncology's upcoming projects, however, bear in mind that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 11% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of Citius Oncology which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Citius Oncology, take a look at Citius Oncology's company page on Simply Wall St. We've also put together a list of important aspects you should further examine:

1. Historical Track Record: What has Citius Oncology's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Citius Oncology's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.